Home › Funds › BOUSSARD & GAVAUDAN GESTION SAS › BBIO
BOUSSARD & GAVAUDAN GESTION SAS position in BBIO
BRIDGEBIO PHARMA INC · Health Care
BOUSSARD & GAVAUDAN GESTION SAS reported holding 35,000 shares of BBIO (BRIDGEBIO PHARMA INC) in its Q3 2026 13F filing — a position valued at US$55.2M, representing 6.52% of its reported portfolio and ranking #3 among its reported holdings. BOUSSARD & GAVAUDAN GESTION SAS has disclosed BBIO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-12 · Source: SEC EDGAR Form 13F-HR
How BOUSSARD & GAVAUDAN GESTION SAS's BBIO position evolved
BOUSSARD & GAVAUDAN GESTION SAS first disclosed a stake in BBIO in Q2 2026 at 29,000 shares (US$51.0M). The position peaked in Q3 2026 at 35,000 shares, worth US$55.2M. Across 2 filings, BOUSSARD & GAVAUDAN GESTION SAS increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 35,000 shares valued at US$55.2M — an increase of 6,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 29.00K | $50.97M | New |
| Q3 2026 | 35.00K | $55.20M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BBIO and 13F data
BBIO (BRIDGEBIO PHARMA INC) is a Health Care company. 47 other funds we track also report a position in BBIO — the largest reported positions include Jupiter Topco LLC (US$1.05B), Janus Henderson Group (US$978.6M), Farallon Capital Management (US$800.1M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BBIO
- Jupiter Topco LLC 14.11M sh · $1.05B · Q2 2026
- Janus Henderson Group 13.18M sh · $978.61M · Q1 2026
- Farallon Capital Management 10.74M sh · $800.14M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 10.74M sh · $800.14M · Q2 2026
- Viking Global Investors 9.95M sh · $741.02M · Q2 2026
- VIKING GLOBAL INVESTORS LP 9.95M sh · $741.02M · Q2 2026
- Aisling Capital Management LP 4.59M sh · $341.83M · Q2 2026
- SC US (TTGP), LTD. 1.86M sh · $138.56M · Q2 2026
- STEELHEAD PARTNERS LLC 70.00M sh · $124.78M · Q2 2026
- CAPSTONE INVESTMENT ADVISORS, LLC 69.87M sh · $124.49M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.55M sh · $115.31M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 1.37M sh · $102.27M · Q2 2026
More on BOUSSARD & GAVAUDAN GESTION SAS
FAQ
How long has BOUSSARD & GAVAUDAN GESTION SAS held BBIO?
BOUSSARD & GAVAUDAN GESTION SAS has disclosed BBIO holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is BOUSSARD & GAVAUDAN GESTION SAS's current position in BBIO?
As of Q3 2026, BOUSSARD & GAVAUDAN GESTION SAS holds 35.00K shares of BBIO (BRIDGEBIO PHARMA INC), valued at $55.20M, representing 6.52% of its reported portfolio and ranking #3.
Has BOUSSARD & GAVAUDAN GESTION SAS been buying or selling BBIO?
In the latest 13F filing (Q3 2026), BOUSSARD & GAVAUDAN GESTION SAS increased its position in BBIO. The position peaked in Q3 2026 at 35.00K shares.
Which other funds hold BBIO?
Other major institutional holders of BBIO include Jupiter Topco LLC, Janus Henderson Group, Farallon Capital Management, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.